{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/prescribing-information/oral-antibiotics/","result":{"pageContext":{"chapter":{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics","depth":2,"htmlHeader":"<!-- begin field e0e41125-d1ad-4dda-9fb3-ef06d179011a --><h2>Oral antibiotics</h2><!-- end field e0e41125-d1ad-4dda-9fb3-ef06d179011a -->","summary":"","htmlStringContent":"<!-- begin item 656b3f84-9f9e-4cfa-b948-e6007a594989 --><!-- end item 656b3f84-9f9e-4cfa-b948-e6007a594989 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c761db7d-9fdb-50c7-8c74-2598a9fc09ce","slug":"prescribing-issues-for-flucloxacillin","fullItemName":"Prescribing issues for flucloxacillin","depth":3,"htmlHeader":"<!-- begin field 161e0927-44ca-456c-aeb1-ea6c960bbbee --><h3>What do I need to know about prescribing flucloxacillin?</h3><!-- end field 161e0927-44ca-456c-aeb1-ea6c960bbbee -->","summary":"","htmlStringContent":"<!-- begin item 227ed8c7-b7ee-4ea6-be66-5957fc6c6c1e --><!-- begin field 92f8bc47-75bc-4d8d-9160-5c1a8282b253 --><ul><li><strong>Flucloxacillin is licensed for the treatment of infected skin conditions, including eczema. </strong></li><li><strong>Dosing regime</strong><ul><li>The usual doses (which should be taken at least 30 minutes before food) are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF for Children, 2017</a>]:<ul><li>Adults and children older than 10 years of age — 250 mg to 500 mg four times a day for 7 days.</li><li>Children 2–10 years of age — 125 mg to 250 mg four times a day for 7 days.</li><li>Children 1 month to 2 years of age — 62.5 mg to 125 mg four times a day for 7 days.</li></ul></li><li>Treatment duration can be extended to 2 weeks if the initial response is inadequate.</li></ul></li><li><strong>Contraindications and cautions </strong><ul><li><strong>Do not prescribe </strong><strong>flucloxacillin to people with:</strong><ul><li>A <em>true </em>penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin.</li><li>History of penicillin-associated hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution to</strong><strong> people with:</strong><ul><li>Hypersensitivity to cephalosporins.</li><li>Hepatic impairment.</li><li>Renal impairment — consider dose reduction, or a reduction in dosing interval, of flucloxacillin in severe renal failure, due to the risk of neurotoxicity.</li></ul></li></ul></li><li><strong>Adverse effects</strong><ul><li><strong>The most common adverse effects of flucloxacillin </strong>are nausea, vomiting, skin rash, and diarrhoea.<ul><li>Consider pseudomembranous colitis, an acute, exudative colitis caused by <em>Clostridium difficile </em>(a Gram-positive toxin-releasing bacillus), if a person develops severe diarrhoea during or after treatment with flucloxacillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis (delayed or immediate) </strong>is a serious but rare adverse effect of flucloxacillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Hepatitis and cholestatic jaundice </strong>may occur very rarely after treatment with flucloxacillin. These reactions are related neither to the dose nor to the route of administration of flucloxacillin, and the onset may be delayed for several weeks (up to 2 months) after treatment has stopped. Risk factors include treatment for more than 2 weeks and increasing age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">CSM, 1992</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">CSM, 2004</a>].</li></ul></li><li><strong>Possible drug interactions with flucloxacillin include:</strong><ul><li><strong>Anticoagulants (for example warfarin)</strong> — monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.<ul><li>Prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.</li></ul></li><li><strong>Methotrexate</strong> — monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.<ul><li>Penicillins may reduce the excretion of methotrexate. The interaction is not usually serious and risk factors are unknown (even people on low doses of methotrexate have been affected).</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not </em>required during or after courses of penicillins.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong>Flucloxacillin is not known to be harmful during pregnancy and breastfeeding </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]<strong>.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">FSRH, 2017</a>]</p><!-- end field 92f8bc47-75bc-4d8d-9160-5c1a8282b253 --><!-- end item 227ed8c7-b7ee-4ea6-be66-5957fc6c6c1e -->","subChapters":[]},{"id":"2ad46257-ff20-5590-9eec-ce91ff94ee9c","slug":"prescribing-issues-for-erythromycin","fullItemName":"Prescribing issues for erythromycin","depth":3,"htmlHeader":"<!-- begin field 0bbccf74-5fe9-4cd1-99f6-b3d9eed9f7e1 --><h3>What do I need to know about prescribing erythromycin?</h3><!-- end field 0bbccf74-5fe9-4cd1-99f6-b3d9eed9f7e1 -->","summary":"","htmlStringContent":"<!-- begin item 440d9f7d-86fe-4f3e-9667-b2a7cbfdbfcd --><!-- begin field 524d1f00-d214-4318-aba7-920291fcfd74 --><ul><li><strong>Erythromycin is licensed for skin and soft tissue infections.</strong></li><li><strong>Dosing regime</strong><ul><li>The usual doses are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF for Children, 2017</a>]:<ul><li>Adults and children older than 8 years of age — 250 mg to 500 mg four times a day for 7 days.</li><li>Children 2–8 years of age — 250 mg four times a day for 7 days.  </li><li>Children 1 month to 2 years of age — 125 mg four times a day for 7 days.</li></ul></li><li>The doses can be doubled in severe infection.</li></ul></li><li><strong>Contraindications and cautions</strong><ul><li><strong>Do not prescribe erythromycin</strong> <strong>to people with:</strong><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution</strong><strong> to people with:</strong><ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. </li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment, due to the risk of ototoxicity. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms in people with myasthenia gravis.</li></ul></li></ul></li><li><strong>Adverse effects</strong><ul><li>Gastrointestinal adverse effects, such as nausea, vomiting, and diarrhoea, are common in people taking erythromycin.</li><li>Consider pseudomembranous colitis, an acute, exudative colitis caused by <em>Clostridium difficile </em>(a Gram-positive toxin-releasing bacillus), if a person develops severe diarrhoea during or after treatment with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li><li>Hepatic dysfunction, including increased liver enzymes and cholestatic hepatitis (with or without jaundice), has been rarely reported with erythromycin.</li></ul></li><li><strong>Possible drug interactions with erythromycin include:</strong><ul><li><strong>Amisulpride </strong>— concurrent use with erythromycin is contraindicated.<ul><li>There is an increased risk of ventricular arrhythmias when erythromycin given with amisulpride.</li></ul></li><li><strong>Cimetidine</strong> — monitor concurrent use closely as a dose reduction of erythromycin may be necessary.<ul><li>Cimetidine may inhibit the metabolism of erythromycin, leading to an increased plasma concentration.</li></ul></li><li><strong>Calcium channel blockers</strong> — concurrent use of erythromycin and calcium channel blockers metabolized by cytochrome CYP3A4 (such as verapamil) should be done cautiously.<ul><li>There is an increased risk of hypotension during concurrent treatment with erythromycin.</li></ul></li><li><strong>Colchicine</strong> — suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).<ul><li>Colchicine toxicity has been reported following concomitant use with erythromycin.</li></ul></li><li><strong>Carbamazepine</strong> — monitor carbamazepine levels within 3–5 days of starting erythromycin, and adjust the dose accordingly. <ul><li>Erythromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).</li></ul></li><li><strong>Domperidone</strong> — concurrent use with erythromycin is contraindicated.<ul><li>Erythromycin increases plasma concentration of domperidone (increased risk of ventricular arrhythmias).</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> — if possible, avoid giving erythromycin to a person who is already taking a drug that can potentially prolong the QT interval.<ul><li>Macrolides can also prolong the QT interval.</li></ul></li><li><strong>Ergotamine and </strong><strong>dihydroergotamine</strong> — concurrent use with erythromycin is contraindicated by the manufacturer of erythromycin.<ul><li>Increased risk of ergotism when erythromycin is given with ergot alkaloids.</li></ul></li><li><strong>Mizolastine </strong>— concurrent use with erythromycin is contraindicated.<ul><li>Macrolides possibly inhibit metabolism of mizolastine.</li></ul></li><li><strong>Pimozide</strong> — concurrent use with erythromycin is contraindicated.<ul><li>Possible increased risk of ventricular arrhythmias when erythromycin given with pimozide.</li></ul></li><li><strong>Quetiapine</strong> — avoid concurrent use.<ul><li> Erythromycin increases plasma concentration of quetiapine.</li></ul></li><li><strong>Reboxetine</strong> — avoidance of macrolides advised by manufacturer of reboxetine.</li><li><strong>Rifabutin</strong> — dose reduction of rifabutin may be needed.<ul><li>Erythromycin possibly increases plasma concentration of rifabutin (increased risk of toxicity). </li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Statins</strong> — there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin. Consider temporarily stopping simvastatin during short-term treatment with erythromycin. </li><li>For atorvastatin — avoid concurrent use with erythromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with erythromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe erythromycin with caution, and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with erythromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline</strong> — consider using clarithromycin (in preference to erythromycin) as clarithromycin normally causes only modest (clinically unimportant) increases in theophylline levels.<ul><li>Concurrent use of erythromycin with high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity (which may present as palpitations, nausea, tremor, and headache). If this is suspected, reduce the dose of theophylline. </li><li>Concurrent treatment may also result in a significant decrease in erythromycin serum concentrations, leading to sub-therapeutic concentrations of erythromycin.</li></ul></li><li><strong>Tolterodine</strong> — concurrent administration with erythromycin is contraindicated by manufacturer of tolterodine.<ul><li>Concurrent use is likely to result in an enhanced risk of cardio toxicity with tolterodine.</li></ul></li><li><strong>Venlafaxine</strong> — avoid concurrent use.<ul><li>There is a risk of ventricular arrhythmias following concurrent use with erythromycin.</li></ul></li><li><strong>Warfarin</strong> — monitor the international normalized ratio (INR) when both drugs are used concurrently (particularly in elderly people), and adjust the warfarin dose accordingly.<ul><li>Erythromycin may enhance the effect of warfarin. This is an established but unpredictable interaction.</li></ul></li><li><strong>Zopiclone</strong> — monitor concurrent use.<ul><li>Erythromycin has been reported to decrease the clearance of zopiclone; this may lead to an increase in the effects of zopiclone. </li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of erythromycin. <ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong>Erythromycin is not known to be harmful during pregnancy and breastfeeding </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]<strong>.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MHRA, 2020</a>]</p><!-- end field 524d1f00-d214-4318-aba7-920291fcfd74 --><!-- end item 440d9f7d-86fe-4f3e-9667-b2a7cbfdbfcd -->","subChapters":[]},{"id":"e86f9ba6-5372-519a-b221-0f6d50d1aaf3","slug":"prescribing-issues-for-clarithromycin","fullItemName":"Prescribing issues for clarithromycin","depth":3,"htmlHeader":"<!-- begin field 65dc2149-704d-4d94-8d1c-f03e2928d4e6 --><h3>What do I need to know about prescribing clarithromycin</h3><!-- end field 65dc2149-704d-4d94-8d1c-f03e2928d4e6 -->","summary":"","htmlStringContent":"<!-- begin item 78cf5442-e053-4fd1-b6b0-708715bc2a5b --><!-- begin field b548faec-c634-4220-81ba-098a316b6fa5 --><ul><li><strong>Clarithromycin is indicated for the treatment of skin and soft tissue infections of mild to moderate severity</strong><strong>.</strong></li><li>The usual doses are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF for Children, 2017</a>]:<ul><li>Adults and children older than 12 years of age — 250 mg to 500 mg (in severe infection) twice daily for 7 days.</li><li>Children 1 month to 12 years of age:<ul><li>Body weight 30–40 kg — 250 mg twice daily.</li><li>Body weight 20–29 kg — 187.5 mg twice daily.</li><li>Body weight 12–19 kg — 125 mg twice daily.</li><li>Body weight 8–11 kg — 62.5 mg twice daily.</li><li>Body weight less than 8 kg — 7.5 mg per kg twice daily.</li></ul></li></ul></li><li><strong>Contraindications and cautions</strong><ul><li><strong>Do not prescribe </strong><strong>clarithromycin </strong><strong>to people with:</strong><ul><li>A history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes arrhythmias.</li><li>Hypokalaemia.</li><li>Severe hepatic impairment in combination with renal impairment.</li></ul></li><li><strong>Prescribe clarithromycin with caution </strong><strong>to people with:</strong><ul><li>Impaired hepatic function (or concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction, including increased liver enzymes and cholestatic hepatitis (with or without jaundice), has been rarely reported with its use.</li><li>Conditions which predispose to QT interval prolongation, such as electrolyte disturbances, and people taking drugs that prolong the QT interval, for example amiodarone, sotalol, terfenadine, and amisulpride — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes arrhythmias.</li><li>Chronic kidney disease (CKD) stages 4 and 5. </li><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT interval prolongation.</li><li>Myasthenia gravis.</li></ul></li></ul></li><li><strong>Adverse effects</strong><ul><li>The most common adverse effects of clarithromycin are nausea, vomiting, abdominal discomfort, and diarrhoea.<ul><li>Consider pseudomembranous colitis, an acute, exudative colitis caused by <em>Clostridium difficile </em>(a Gram-positive toxin-releasing bacillus), if a person develops severe diarrhoea during or after treatment with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Hepatotoxicity (including cholestatic jaundice) and rash have less frequently been reported.</li><li>Anaphylaxis is rarely associated with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li>Reversible hearing loss (sometimes with tinnitus) can occur after large doses of clarithromycin.</li><li>Other adverse effects reported rarely or very rarely include pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul></li><li><strong>Possible drug interactions with clarithromycin include:</strong><ul><li><strong>Carbamazepine</strong> — reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin, or consider prescribing azithromycin, if appropriate.<ul><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Calcium channel blockers</strong> — concurrent use of clarithromycin and calcium channel blockers metabolized by cytochrome CYP3A4 (such as verapamil, amlodipine, and diltiazem) should be done cautiously.<ul><li>There is an increased risk of hypotension during concurrent treatment with clarithromycin.</li></ul></li><li><strong>Colchicine</strong> — suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).<ul><li>Clarithromycin possibly increases risk of colchicine toxicity. </li></ul></li><li><strong>Domperidone</strong> — avoid<strong> </strong>concurrent use.<ul><li>There is a possible increased risk of ventricular arrhythmias when clarithromycin given with domperidone.</li></ul></li><li><strong>Drugs that prolong the QT interval </strong>(such as anti-arrhythmics, antipsychotics, and tricyclic antidepressants) — seek advice from a medical microbiologist regarding a suitable alternative antibiotic.<ul><li>All macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.</li></ul></li><li><strong>Drugs that cause hypokalaemia </strong>(such as diuretics, corticosteroids, short-acting beta2-agonists) — seek advice from a medical microbiologist regarding a suitable alternative antibiotic.<ul><li>Hypokalaemia is a risk factor for QT prolongation.</li></ul></li><li><strong>Ergotamine and </strong><strong>dihydroergotamine</strong> — concurrent use with clarithromycin is contraindicated by the manufacturer of clarithromycin.<ul><li>Increased risk of ergotism when clarithromycin is given with ergot alkaloids.</li></ul></li><li> <strong>Ivabradine </strong>— avoid concomitant use.<ul><li>Clarithromycin possibly increases plasma concentration of ivabradine.</li></ul></li><li><strong>Midazolam</strong> — concurrent use should be done with caution.<ul><li>Clarithromycin inhibits metabolism of midazolam (increased plasma concentration with increased sedation).</li></ul></li><li><strong>Mizolastine</strong> — avoid concurrent use. <ul><li>Macrolides possibly inhibit metabolism of mizolastine.</li></ul></li><li><strong>Pimozide</strong> — concurrent use with clarithromycin is contraindicated.<ul><li>Possible increased risk of ventricular arrhythmias when clarithromycin given with pimozide.</li></ul></li><li><strong>Quetiapine</strong> — avoid concurrent use.<ul><li> Clarithromycin increases plasma concentration of quetiapine.</li></ul></li><li><strong>Reboxetine</strong> — avoidance of macrolides advised by manufacturer of reboxetine.</li><li><strong>Rifabutin</strong> — dose reduction of rifabutin may be needed.<ul><li>Clarithromycin possibly increases plasma concentration of rifabutin (increased risk of toxicity). </li></ul></li><li><strong>Sildenafil</strong> — consider reducing initial dose of sildenafil.<ul><li>Clarithromycin increases the plasma concentration of sildenafil.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin, as simvastatin is extensively metabolized by CYP3A4. If clarithromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin — avoid concurrent use with clarithromycin as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (that is 10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism, so an interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Warfarin</strong> — occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Antidiabetic drugs and insulin</strong> — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly, and adjust the antidiabetic drug (and/or insulin) dose accordingly.</li></ul></li><li><strong>Contraceptives</strong> — additional contraceptive precautions are <em>not </em>required during or after a course of clarithromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/oral-antibiotics/#prescribing-issues-for-erythromycin\">Erythromycin</a> is the macrolide of choice in pregnant and breastfeeding women. Clarithromycin should only be considered if the woman cannot tolerate erythromycin and there is no suitable alternative.</strong></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">FSRH, 2017</a>]</p><!-- end field b548faec-c634-4220-81ba-098a316b6fa5 --><!-- end item 78cf5442-e053-4fd1-b6b0-708715bc2a5b -->","subChapters":[]},{"id":"5c4ce61c-7307-51fa-8282-c095fad1f8af","slug":"usage-instructions","fullItemName":"Usage instructions","depth":3,"htmlHeader":"<!-- begin field 8742049c-9d29-4503-b7c0-e6f771bf2c4e --><h3>What should I advise on how to use oral antibiotics?</h3><!-- end field 8742049c-9d29-4503-b7c0-e6f771bf2c4e -->","summary":"","htmlStringContent":"<!-- begin item e7ca56b3-44a9-4b90-a198-03a2aeb0f9b6 --><!-- begin field a75bb680-0fcf-4a8d-88dd-9891e79b9b2e --><ul><li><strong>Advise the person:</strong><ul><li>To complete the treatment course as directed.</li><li>To continue treatment with topical corticosteroids and emollients while taking antibiotics.</li><li>That gastrointestinal adverse effects (such as nausea, vomiting, or diarrhoea) can sometimes occur with all antibiotics. However, these are particularly common with erythromycin.<ul><li>If the person experiences severe symptoms, they should return for a trial of an alternative antibiotic (for example clarithromycin).</li></ul></li><li>That additional contraceptive precautions are <em>not </em>required during or after courses of broad spectrum antibiotics.<ul><li>Advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong>Also advise people taking flucloxacillin that </strong>some people are allergic to penicillin antibiotics (including flucloxacillin). They should seek urgent medical advice if they develop a severe rash; there is swelling of the face, hands or feet; or they feel short of breath.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">FSRH, 2017</a>]</p><!-- end field a75bb680-0fcf-4a8d-88dd-9891e79b9b2e --><!-- end item e7ca56b3-44a9-4b90-a198-03a2aeb0f9b6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}